tiprankstipranks
Advertisement
Advertisement

HK:2162 Stock Latest News

Keymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric Cancer
Company AnnouncementsKeymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric Cancer
6d ago
2162
Keymed’s CM512 Wins China Breakthrough Status, Advances in Multiple Phase II Trials
PremiumCompany Announcements
Keymed’s CM512 Wins China Breakthrough Status, Advances in Multiple Phase II Trials
11d ago
2162
Keymed Biosciences Swings to Profit on Kangyueda Surge and Licensing Windfall
PremiumCompany Announcements
Keymed Biosciences Swings to Profit on Kangyueda Surge and Licensing Windfall
19d ago
2162
Keymed Biosciences Shareholders Approve All AGM Resolutions, Renew Capital Mandates
PremiumCompany Announcements
Keymed Biosciences Shareholders Approve All AGM Resolutions, Renew Capital Mandates
1M ago
2162
Keymed Biosciences Banks US$257 Million From Ouro Medicines Sale as Gilead-Lakefront Alliance Advances CM336
PremiumCompany Announcements
Keymed Biosciences Banks US$257 Million From Ouro Medicines Sale as Gilead-Lakefront Alliance Advances CM336
2M ago
2162
Keymed Biosciences Sets AGM to Approve Accounts, Board Changes and New Share Mandate
PremiumCompany AnnouncementsKeymed Biosciences Sets AGM to Approve Accounts, Board Changes and New Share Mandate
3M ago
2162
Keymed Biosciences Details Gain and Capital Plans From Ouro Medicines Stake Disposal
Premium
Company Announcements
Keymed Biosciences Details Gain and Capital Plans From Ouro Medicines Stake Disposal
4M ago
2162
Keymed Biosciences boosts revenue on Kangyueda push while deepening R&D pipeline
Premium
Company Announcements
Keymed Biosciences boosts revenue on Kangyueda push while deepening R&D pipeline
4M ago
2162
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
PremiumMarket News
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
4M ago
GSK
GILD
Keymed Biosciences to Realize Up to US$320 Million From Ouro Medicines Exit
PremiumCompany Announcements
Keymed Biosciences to Realize Up to US$320 Million From Ouro Medicines Exit
4M ago
2162
Keymed Biosciences Sets March 26 Board Meeting to Approve 2025 Results and Consider Final Dividend
PremiumCompany Announcements
Keymed Biosciences Sets March 26 Board Meeting to Approve 2025 Results and Consider Final Dividend
5M ago
2162
Keymed Gains US$45 Million Milestone as AstraZeneca Starts Phase III Trial of Core Cancer Drug
PremiumCompany Announcements
Keymed Gains US$45 Million Milestone as AstraZeneca Starts Phase III Trial of Core Cancer Drug
5M ago
2162
Keymed Biosciences’ Strategic Positioning and Stapokibart’s Market Potential in Biotech Sector
PremiumRatingsKeymed Biosciences’ Strategic Positioning and Stapokibart’s Market Potential in Biotech Sector
9M ago
Keymed Biosciences Reports Strong Revenue Growth Amid Leadership Change
Premium
Company Announcements
Keymed Biosciences Reports Strong Revenue Growth Amid Leadership Change
11M ago
2162
Keymed Biosciences Schedules Board Meeting to Review Interim Results
Premium
Company Announcements
Keymed Biosciences Schedules Board Meeting to Review Interim Results
12M ago
2162
Keymed Biosciences Announces Successful AGM Resolutions
PremiumCompany Announcements
Keymed Biosciences Announces Successful AGM Resolutions
1y ago
2162
Keymed Biosciences Completes Share Placement and Subscription, Raising HK$853.77 Million
PremiumCompany Announcements
Keymed Biosciences Completes Share Placement and Subscription, Raising HK$853.77 Million
1y ago
2162
Keymed Biosciences Announces Share Placement and Subscription to Raise HK$853.77 Million
PremiumCompany Announcements
Keymed Biosciences Announces Share Placement and Subscription to Raise HK$853.77 Million
1y ago
2162
Keymed Biosciences Announces 2025 Annual General Meeting and Key Resolutions
PremiumCompany Announcements
Keymed Biosciences Announces 2025 Annual General Meeting and Key Resolutions
1y ago
2162
Keymed Biosciences to Review Annual Results and Dividend
PremiumCompany AnnouncementsKeymed Biosciences to Review Annual Results and Dividend
1y ago
2162
Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment
Premium
Company Announcements
Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment
1y ago
2162
Keymed Biosciences Licenses CM355 to Prolium for Global Development
Premium
Company Announcements
Keymed Biosciences Licenses CM355 to Prolium for Global Development
2y ago
2162

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >